Topic:Biocompatibility
Biocompatibility in horses refers to the compatibility of materials or substances with equine tissues and physiological processes. This concept is particularly relevant in the context of veterinary medical devices, implants, and pharmaceuticals used in equine care. Biocompatibility assessments are conducted to ensure that these materials do not provoke adverse reactions, such as inflammation, toxicity, or rejection when introduced into the horse's body. These evaluations involve a range of in vitro and in vivo tests to analyze interactions at the cellular and systemic levels. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, findings, and implications of biocompatibility assessments in equine health management.
Direct current stimulation of bone production in the horse: preliminary study with a “gap healing” model. The effect of a 20-microA direct-current implantable bone growth stimulator (BGS) on bone production with a "gap healing" model in the horse was evaluated. The right and left 4th metatarsal bones (Mt-4) were used in 7 adult horses to create the "gap healing" model. A 4-mm section of the Mt-4 bone was resected bilaterally in each horse. The BGS was surgically placed into the 7 left Mt-4 defects. The 7 right Mt-4 defects served as controls. Six horses survived the 16-week experimental period. Signs of pain, decreased range of limb motion, or lameness was not observed in any animal during the 16 ...
Fatigue characteristics and biocompatability of a totally implantable bone growth stimulator in ponies. Materials fatigue and gross biocompatability of an implantable bone growth stimulator (BGS) were assessed in a 6-month trial using 6 ponies. The forelegs of each pony were implanted with a BGS; the right leg implant had the cathode and cathode lead preconnected by the manufacturer, and the left leg implant was connected at surgery. Evaluation was by radiographic and clinical examination at the beginning and end of the experimental period. Six of the 12 cathode leads (50%) and 7 of the 12 cathodes (58%) were broken at 6 months. All of the implanted preconnected cathode and insulated cathode lea...
An assessment of filamentous carbon fibre for the treatment of tendon injury in the horse. The results of an assessment of carbon fibre for biological use are given, with particular reference to the clinical use of the material in the treatment of equine tendon injury. Biocompatability of the fibres is assessed using fibroblast cell cultures and replacement of normal tendon with carbon fibre prostheses in experimental animals. The rationale and technique for using this material in clinical cases of tendon injury in the racehorse are described. Results are given from 62 implant operations in a limited series of 40 horses.